A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial)

Ann Surg Oncol. 2022 Sep;29(9):5375-5376. doi: 10.1245/s10434-022-11917-2. Epub 2022 Jun 6.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • BRCA1 Protein / genetics
  • BRCA2 Protein / genetics
  • Fanconi Anemia Complementation Group N Protein / genetics
  • Germ-Line Mutation
  • Humans
  • Mutation
  • Pancreatic Neoplasms* / drug therapy
  • Pancreatic Neoplasms* / genetics
  • Pancreatic Neoplasms* / surgery
  • Phthalazines* / therapeutic use
  • Piperazines / therapeutic use

Substances

  • BRCA1 Protein
  • BRCA1 protein, human
  • BRCA2 Protein
  • BRCA2 protein, human
  • Fanconi Anemia Complementation Group N Protein
  • PALB2 protein, human
  • Phthalazines
  • Piperazines
  • olaparib